WA
ALNY icon

Waddell & Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Waddell & Associates’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-618
Closed -$204K – 547
2026
Q1 		$204K Sell
618
-399
-39% -$136K 0.01% 419
2025
Q4 		$404K Sell
1,017
-1
-0.1% -$443 0.03% 211
2025
Q3 		$464K Buy
+1,018
New +$415K 0.04% 146

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Waddell & Associates's ALNY Position: Q2 2026 in Review

Waddell & Associates sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 618 shares — an estimated $204K sold.

Waddell & Associates first reported a position in ALNY in Q3 2025 and held it in 3 quarters. The position peaked at $464K in Q3 2025. 148 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Waddell & Associates reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Waddell & Associates sold 618 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $204K.
  • Waddell & Associates first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Waddell & Associates's Alnylam Pharmaceuticals position peaked at $464K in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.